Keyphrases
Area under the Concentration-time Curve
50%
Bacteriostatic
75%
Bacteriostatic Activity
25%
Certain Factor
25%
Cmax
50%
Dose Effect
25%
Dose Finding
25%
Dose Rate
25%
Dose-response Model
25%
Dosing Schedule
50%
Drug Combination
25%
Effective Dose
25%
Elimination Half-life
25%
Escherichia Coli
25%
Escherichia Coli ATCC 25922
50%
Glycylcycline
100%
Gram-negative Bacteria
100%
Gram-positive
100%
In Vivo Efficacy
25%
Klebsiella Pneumoniae (K. pneumoniae)
75%
Maximal Effect
50%
Maximum Permissible Concentration
25%
Microorganisms
25%
Murine Thigh Infection Model
25%
Neutropenic Mouse
25%
Pharmacodynamic Interactions
100%
Pharmacodynamics
25%
Pharmacokinetic Parameters
25%
Pharmacokinetic Study
25%
Rational Design
25%
S. Pneumoniae
50%
Serum Protein Binding
25%
Staphylococcus Aureus
25%
Streptococcus Pneumoniae
25%
Tetracycline
25%
Tetracycline Resistant Bacteria
25%
Twice-daily Dosing
25%
Unbound Drug
25%
Immunology and Microbiology
Body Weight
33%
Dose Response
33%
Elimination Half-Life
33%
Escherichia coli
100%
Gram-Negative Bacteria
100%
Klebsiella pneumoniae
33%
Microorganism
33%
Minimum Inhibitory Concentration
100%
Mouse
66%
Pharmacodynamics
100%
Pharmacokinetics
66%
Plasma Protein Binding
33%
Pneumococcus
66%
Staphylococcus Aureus
33%
Streptococcus Pneumoniae
33%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Drug
25%
Dosing Studies
25%
Elimination
25%
Escherichia coli
50%
Escherichia Coli Pneumonia
25%
Glycylcycline Derivative
100%
Gram Negative Bacterium
100%
Infection
50%
Klebsiella pneumoniae
25%
Microorganism
25%
Mouse
50%
Pamicogrel
25%
Pharmacodynamic Parameter
25%
Pharmacodynamics
100%
Pharmacokinetic Parameter
25%
Pharmacokinetics
25%
Plasma Protein Binding
25%
Staphylococcus Aureus
25%
Streptococcus Pneumoniae
25%
Tetracycline
50%